US Patent

US11878022 — Hydrochlorothiazide compositions

Method of Use · Assigned to Novitium Pharma LLC · Expires 2044-01-23 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a highly pure hydrochlorothiazide powder for oral suspension and its reconstituted product for treating hypertension and edema.

USPTO Abstract

Disclosed herein is a powder for oral suspension and a reconstituted product thereof comprising highly pure hydrochlorothiazide, which is useful for treating hypertension and edema.

Drugs covered by this patent

Microzide (hydrochlorothiazide) · Generic (originally Merck)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4138`	—	Microzide

Patent Metadata

Patent number: US11878022
Jurisdiction: US
Classification: Method of Use
Expires: 2044-01-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Novitium Pharma LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.